A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. - Wikidata - awgldk - TriplyDB

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.

http://www.wikidata.org/entity/Q34326476

about

Targeting the CCL2-CCR2 signaling axis in cancer metastasis Therapeutic potential of chemokine signal inhibition for metastatic breast cancer Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic Agents Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy The interaction of anticancer therapies with tumor-associated macrophages CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages Targeting tumor-associated macrophages to combat pancreatic cancer Overexpression of lipocalins and pro-inflammatory chemokines and altered methylation of PTGS2 and APC2 in oral squamous cell carcinomas induced in rats by 4-nitroquinoline-1-oxide Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages Diallyl disulfide inhibits TNFα-induced CCL2 release by MDA-MB-231 cells.Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases Molecular basis of lateral force spectroscopy nano-diagnostics: computational unbinding of autism related chemokine MCP-1 from IgG antibody Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2.Adaptation of ovarian cancer cells to the peritoneal environment: Multiple mechanisms of the developmental patterning gene HOXA9 Anti-CCL2: building a reservoir or opening the floodgates to metastasis?Crosstalk between Tumor Cells and Macrophages in Stroma Renders Tumor Cells as the Primary Source of MCP-1/CCL2 in Lewis Lung Carcinoma.Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.Opportunities and challenges in combination gene cancer therapy.A CCL8 gradient drives breast cancer cell dissemination.Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013 Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment Tumor-associated macrophages: from basic research to clinical application.A multi-targeted approach to treating bone metastases.Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches Tumor-associated macrophages and anti-tumor therapies: complex links.The Promise of Targeting Macrophages in Cancer Therapy.CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro.Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer.Tumour-associated macrophages as treatment targets in oncology.Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity.Tumor-associated macrophages: implications in cancer immunotherapy.Macrophage Metabolism As Therapeutic Target for Cancer, Atherosclerosis, and Obesity.Nanomedicine Strategies to Target Tumor-Associated Macrophages.Tumor-Associated Macrophages as Target for Antitumor Therapy.Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts.CXC and CC chemokines as angiogenic modulators in nonhaematological tumors.Tumor-associated macrophages, potential targets for cancer treatment.Investigation of proliferation and migration of tongue squamous cell carcinoma promoted by three chemokines, MIP-3α, MIP-1β, and IP-10.

P2860

Q26765184-C8028714-EB43-4354-8766-010E05E0DCDC Q26798116-38B2F3FA-9471-4765-A154-102847B41ADA Q26830743-70412125-F88D-4F89-AFA7-A47C9B51ABE5 Q26993238-B8EC57B8-E05A-41D8-900F-DB8FE8C0F8D8 Q27016634-0E97F849-1A77-4F29-BBEC-C55CAE4D430F Q27308841-02E51509-B7CB-4C72-AC5A-994B2A0F91FF Q28076103-BC5FCFCE-E887-4B78-B236-FECEBF7ED653 Q28543174-E34190F6-5880-4151-A7F2-0322CAFABD32 Q33415914-E4D5A30B-199A-4213-A7A5-C641BF49B11B Q34044797-E4F97DC9-54B6-46E0-9098-E42917F49F07 Q34056943-B7781846-140F-404B-B047-2A75C3511C10 Q34132305-7FDE7AC5-A534-4C0A-96B8-E01B2470F36F Q34995989-C471509D-81D6-4DAD-AD9B-8982CEAA4131 Q35611323-844D9AB2-579C-4719-95CA-FBA483CED26F Q35623134-9C44F2C2-0F92-4583-A9F3-6DFEB271BD9B Q35627081-3825FB59-7255-499B-B66E-37AE62AC2765 Q35782923-6734C198-3126-4A4A-AA27-ADFE59DFEEF1 Q36213735-B7B46B60-E97E-4447-BA83-16A249008F7D Q36709856-B5E6BA99-C41F-4508-83CF-A255E10399AA Q37118663-C9F8974F-74DE-4AF2-AECA-A5BEA87D699B Q37418545-32B1C4AE-421C-4583-9B07-F961816E966B Q37496388-F8FF49FE-D2EE-4D5C-995C-67AE79FB0F7B Q37520325-49D6CB45-22A9-49E8-ACE5-D2443F2A1C0E Q37671174-39CF6FF9-C6EA-4DFC-9C00-BB8BF86F33E2 Q38175846-812F923D-7373-4C7B-B6CA-C3680CE21626 Q38689153-4E75CEF8-3C68-4234-9FEE-76F8205B366F Q38766176-3AC47CFE-BAEB-46D6-99BC-DD79ABFB1C32 Q38877313-75CCDBCF-767D-4EAE-9755-9D08806B723C Q38960744-FC9DA2A4-007C-4D6D-A274-40BC4868D9D1 Q39096364-FC534262-798E-4C6E-8C5C-1C72CD836520 Q39100693-96E7B2CE-9E73-4792-9A2C-06028C70904F Q39144794-08A91C5A-5DA6-450A-83F0-4CB11A41FC2E Q39148281-A4DF898A-DA7E-4F0E-914F-9E47FDA839F9 Q39210018-56E2B092-EB3C-4D1D-9909-27D58E4DF283 Q39283111-596A184B-7857-418C-B8F8-AB6F6717C480 Q39403895-34C3AE5A-2C1B-4482-8236-3A5F77D0942F Q40124047-697D9DDD-491F-4873-9BD1-AB148A475ED1 Q40724369-0CE876D6-9AA0-4BBF-8839-77F0F561A815 Q41318642-F757B36B-1BA8-4B71-A36C-3395DC9EDABB Q41633780-F2D42E58-DF9C-4726-B69C-13EE0B2C5167

P2860

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.

http://www.wikidata.org/entity/Q34326476

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A first-in-human, first-in-cla ...... in patients with solid tumors.

@ast

A first-in-human, first-in-cla ...... in patients with solid tumors.

@en

A first-in-human, first-in-cla ...... in patients with solid tumors.

@nl

type

label

A first-in-human, first-in-cla ...... in patients with solid tumors.

@ast

A first-in-human, first-in-cla ...... in patients with solid tumors.

@en

A first-in-human, first-in-cla ...... in patients with solid tumors.

@nl

prefLabel

A first-in-human, first-in-cla ...... in patients with solid tumors.

@ast

A first-in-human, first-in-cla ...... in patients with solid tumors.

@en

A first-in-human, first-in-cla ...... in patients with solid tumors.

@nl

P1433

Q34326476-52C2CAAF-8352-4D68-AA79-E7EEE50CF019

P1476

Q34326476-34709F5A-50CF-4F13-AD05-21C155E588C6

P2093

Q34326476-4139988A-B4F6-48D2-AE92-9B56722BB558

Q34326476-53026F1C-F8B1-43B4-9AF1-90B87B8BC58B

Q34326476-5723B6BA-F4BA-441F-BE9A-E9E141D6ACE2

Q34326476-66E8E33C-FB5D-4EBE-B779-AE8845F4FE12

Q34326476-6F06BE42-BC2C-4869-8D56-3750AA5C340A

Q34326476-B4AA19AC-A0F9-487B-B302-66733D9DEEAA

Q34326476-C752527B-CD9D-4984-83D7-BAF7AD1EC937

Q34326476-D69E5BBE-ABCE-4452-AD6D-BA47358EF391

Q34326476-E3B3612D-FF06-4FA7-9FD8-F45B44FDCEF2

Q34326476-EE3CBD7F-7EC5-4A70-99AB-A0C6F4BFFFF4

P2860

Q34326476-07F9B865-DE40-44E9-BFF1-70FF9EC8DF7B

Q34326476-1C2FE84D-BDE3-4D03-89DF-49E0C6E26A97

Q34326476-270A4993-FDF6-4BD8-984E-141F03FB836E

Q34326476-2BB9BA1E-9D06-4261-B7C1-4C1986EA4881

Q34326476-2BFC26F4-51A3-4008-8F54-0958A2AEE055

Q34326476-2EBF2CC5-42BE-4DCD-BEED-9A0FFAB2EC6E

Q34326476-3A2C7BF8-8885-489B-A8DC-702611894FF1

Q34326476-41FD0436-21B5-4925-A1A3-D90D3DC3954C

Q34326476-455332AC-1C8F-4261-8A9B-325434742C31

Q34326476-490A48F3-EC0B-407F-90B1-232C0317CA1A

P2888

Q34326476-60D2557C-0FF1-47BE-8B98-B60F84EC3F01

P304

Q34326476-470E54A1-FC03-4D2A-866D-A48DF1F01D78

P31

Q34326476-D6692949-4F67-40D3-B02C-86920DF10C2E

P356

Q34326476-BC3D5A93-2A28-4425-A231-D2E09F16602A

P433

Q34326476-3DE24D95-FFFA-4F81-8B15-68343510E4FD

P478

Q34326476-5FD23FAC-543D-4DDA-82F6-8ADD379CC64C

P50

Q34326476-1A44718D-407B-4EA7-A494-820B70E7E799

Q34326476-6D1CB5C0-0035-4B0D-9ACA-ACC1536A561A

P577

Q34326476-5C34B52C-5983-4588-AAEE-A1A1098B82B2

P6179

Q34326476-072D822F-F840-4A5D-AF5C-7BA058AB6842

P698

Q34326476-D4949CD9-0219-4BF6-85A1-66FDCBB30231

P921

Q34326476-2020C1E5-69C1-49F8-BF5F-F8123FC46E5F

P356

S00280-013-2099-8

P1433

Cancer Chemotherapy and Pharmacology

P1476

A first-in-human, first-in-cla ...... in patients with solid tumors

@en

P2093

Amita Patnaik

http://www.w3.org/2001/XMLSchema#string

Anthony W Tolcher

http://www.w3.org/2001/XMLSchema#string

Birge Berns

http://www.w3.org/2001/XMLSchema#string

Brenda J Tromp

http://www.w3.org/2001/XMLSchema#string

Christina Messiou

http://www.w3.org/2001/XMLSchema#string

David Olmos

http://www.w3.org/2001/XMLSchema#string

George Wang

http://www.w3.org/2001/XMLSchema#string

Johann S de Bono

http://www.w3.org/2001/XMLSchema#string

Kyri Papadopoulos

http://www.w3.org/2001/XMLSchema#string

Peter C Fong

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

CCL2 is a potent regulator of prostate cancer cell migration and proliferation.

CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration.

Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients.

Dose escalation methods in phase I cancer clinical trials.

P2888

s00280-013-2099-8

P304

1041-1050

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-013-2099-8

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Frances R Balkwill

Shahneen K Sandhu

P577

2013-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1042756221

http://www.w3.org/2001/XMLSchema#string

P698

23385782

http://www.w3.org/2001/XMLSchema#string

P921